oestrogen receptorstable phenotypeOestrogen receptor (ER) expression in breast cancer is regarded as a phenotype that may change during the natural history of the disease or during endocrine therapy. It has been suggested that in up to 70% of tumours that show acquired resistance the mechanism may...
(1994) Oestrogen receptor (ESR) polymorphisms and breast cancer suscep- tibility. Hum. Genet. 94: 665-670.Tone Ikdahl Anderson,Ketil Riddervold Heimdal,Martina Skrede,Kjell Tveit,K?re Berg,Anne-Lise B?rresen. Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility[J] 1994,...
Keywords advanced breast cancer estrogen receptor downregulation ‘Faslodex’ fulvestrant postmenopausal sequencing Introduction Over the past 25 years, the prevalence of breast cancer has been increasing steadily in almost all populations. In the USA, the incidence has been rising by ∼1% per year, ...
Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Piccart M,Parker LM,Pritchard KI.Oestrogen receptor downregulation:an opportunity for extending the window of endocrine therapy in advanced breast cancer[J]... M Piccart,LM Parker...
Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability. The concentration of cellular oestrogen receptor (RE) was measured in both the soluble and nuclear-pellet fractions of biopsies from 1,000 breast cancers. ... RE Leake,L Laing,KC Calman,... ...
Although oestrogen is essential for the development of the normal breast, adult mammary stem cells are known to be oestrogen receptor alpha (ER) negative and rely on paracrine signals in the mammary epithelium for mediation of developmental cues. However
Women with early-stage oestrogen receptor (ER)-positive (ER) breast cancer who receive standard endocrine therapy for 5 years remain at risk of distant recurrence for at least 15 years after treatment discontinuation. The extension of the duration of adjuvant endocrine therapy to 10 years has ...
The latest ASCO/CAP guideline has recommended to report oestrogen receptor (ER) low cases (ERlo; 1–10%) as “ER low positive category”, prompting us to compare the clinicopathologic features, biomarkers, survival and treatment of the ERlo cases with ot
afix user dir permissions 固定用户dir允许[translate] aThe prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer. 肿瘤stroma比率的预断意义在雌激素感受器官正面乳腺癌。[translate]
Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients--an i... Down-regulation of heat-shock protein 70 (HSP-70) correlated with respon- siveness to neoadjuvant aromatase inhibitor therapy in breast cancer ...